8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Apr 20, 2026·SEC
Material company update
Mar 18, 2026·SEC
Ovid Therapeutics Inc.(OVID)Earnings, Financials & Key Ratios
OVID•NASDAQ
Price updated Jun 19, 2026
AboutOvid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.Show more
- Revenue$7M+1181.3%
- EBITDA-$42M+31.2%
- Net Income-$17M+34.1%
- EPS (Diluted)-0.24+35.1%
- Gross Margin95.86%-4.1%
- EBITDA Margin-581.07%+94.6%
- Operating Margin-585.2%+94.6%
- Net Margin-240.13%+94.9%
- ROE-17.51%+48.3%
OVID Key Insights
Ovid Therapeutics Inc. (OVID) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 26.5%
- ✓High quality earnings: Operating CF exceeds net income
- ✓Trading at only 1.3x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Sales declining 10.5% over 5 years
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when OVID posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
OVID Price & Volume
Ovid Therapeutics Inc. (OVID) stock price & volume — 10-year historical chart
Loading chart...
OVID Growth Metrics
Ovid Therapeutics Inc. (OVID) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-10.48%
3 Years68.99%
TTM1199.63%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM3.23%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM1.17%
Return on Capital
10 Years-53.2%
5 Years-13.07%
3 Years-45.95%
Last Year-37.84%
OVID Recent Earnings
Ovid Therapeutics Inc. (OVID) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 9/12 qtrs (82%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.12+0.0%
$0.12
Rev
—
$56,667
Q2 2026
Mar 18, 2026Metric
Actual
Est
EPS
$0.06+160.0%
$0.10
Rev
$718,000+817.6%
$78,250
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.17-13.3%
$0.15
Rev
$132,000+110.9%
$62,600
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.06+62.5%
$0.16
Rev
$6M+10126.6%
$61,330
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.12vs $0.12+0.0% | —vs $56,667 |
| Q2 2026 | Mar 18, 2026 | $0.06vs $0.10+160.0% | $718,000vs $78,250+817.6% |
| Q4 2025 | Nov 12, 2025 | $0.17vs $0.15-13.3% | $132,000vs $62,600+110.9% |
| Q3 2025 | Aug 13, 2025 | $0.06vs $0.16+62.5% | $6Mvs $61,330+10126.6% |
Based on last 12 quarters of dataView full earnings history →
OVID Peer Comparison
Ovid Therapeutics Inc. (OVID) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 LGND | 5.51B | 274.88 | 44.84 | 60.4% | 55.95% | 16.19% | 0.44 | |
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 PTCT | 6.55B | 78.98 | 10.15 | 114.51% | -22.58% | |||
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 KRYS | 10.26B | 348.06 | 50.89 | 33.94% | 53.92% | 19.25% | 0.01 | |
 ARVN | 494.88M | 7.67 | -5.99 | -0.3% | -247.54% | -44.39% | 0.02 |
Compare OVID vs Peers
Ovid Therapeutics Inc. (OVID) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OVID Income Statement
Ovid Therapeutics Inc. (OVID) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 12.62M | 208.38M | 1.5M | 392K | 566K | 7.25M | 7.12M |
Revenue Growth % | - | - | - | - | 1551.57% | -99.28% | -73.91% | 44.39% | 1181.27% | 1199.63% |
Cost of Goods Sold | 80.31K | 141.73K | 0 | 0 | 0 | 0 | 0 | 0 | 300K | 35K |
COGS % of Revenue | - | - | - | - | - | - | - | - | 4.14% | - |
Gross Profit | -80.31K▲ 0% | -142K▼ 76.8% | 0▲ 100.0% | 12.62M▲ 0% | 208.38M▲ 1551.6% | 1.5M▼ 99.3% | 392K▼ 73.9% | 566K▲ 44.4% | 6.95M▲ 1128.3% | 7.09M▲ 0% |
Gross Margin % | - | - | - | 100% | 100% | 100% | 100% | 100% | 95.86% | 99.51% |
Gross Profit Growth % | -42.11% | -76.81% | 100% | - | 1551.57% | -99.28% | -73.91% | 44.39% | 1128.27% | - |
Operating Expenses | 65.01M | 52.93M | 61.41M | 94.05M | 84.17M | 57.05M | 59.67M | 62.45M | 49.39M | 54.82M |
OpEx % of Revenue | - | - | - | 745.4% | 40.39% | 3796.44% | 15222.7% | 11033.75% | 681.07% | - |
Selling, General & Admin | 15.04M | 19.14M | 19.25M | 30.63M | 37.23M | 32.43M | 29.59M | 25.68M | 24.11M | 24.75M |
SG&A % of Revenue | - | - | - | 242.77% | 17.87% | 2158.18% | 7547.19% | 4537.63% | 332.45% | - |
Research & Development | 49.97M | 33.79M | 46.86M | 64.12M | 46.94M | 24.62M | 28.59M | 36.77M | 25.58M | 30.07M |
R&D % of Revenue | - | - | - | 508.17% | 22.53% | 1638.23% | 7292.86% | 6495.94% | 352.76% | - |
Other Operating Expenses | 0 | 0 | -4.7M | -700K | 1.1K | 510 | 1.5M | 1K | -300K | 0 |
Operating Income | -65.01M▲ 0% | -52.93M▲ 18.6% | -61.41M▼ 16.0% | -81.43M▼ 32.6% | 124.21M▲ 252.5% | -55.55M▼ 144.7% | -59.28M▼ 6.7% | -61.88M▼ 4.4% | -42.44M▲ 31.4% | -47.73M▲ 0% |
Operating Margin % | - | - | - | -645.4% | 59.61% | -3696.44% | -15122.7% | -10933.75% | -585.2% | -670.25% |
Operating Income Growth % | -188.48% | 18.58% | -16.02% | -32.6% | 252.53% | -144.72% | -6.72% | -4.39% | 31.42% | - |
EBITDA | -64.93M | -52.79M | -61.15M | -81.12M | 124.45M | -54.17M | -58.71M | -61.27M | -42.14M | -47.57M |
EBITDA Margin % | - | - | - | -642.96% | 59.72% | -3604.5% | -14977.81% | -10825.44% | -581.07% | -667.9% |
EBITDA Growth % | -188.84% | 18.69% | -15.84% | -32.65% | 253.4% | -143.53% | -8.39% | -4.36% | 31.23% | 15.66% |
D&A (Non-Cash Add-back) | 80.31K | 141.73K | 255K | 306.85K | 237.08K | 1.38M | 568K | 613K | 300K | 167K |
EBIT | -64.81M | -52.93M | -61.41M | -81.43M | 124.21M | -55.55M | -57.58M | -58.38M | -42.44M | -47.73M |
Net Interest Income | 0 | 0 | 948.22K | 395.4K | 0 | 0 | 4.9M | 3.9M | 0 | 0 |
Interest Income | 201.51K | 952.07K | 948.22K | 395.4K | 0 | 0 | 4.9M | 3.9M | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 201.51K | 952.07K | 948.22K | 395.4K | -45.69K | 1.38M | 6.94M | 35.45M | 25.02M | 23.57M |
Pretax Income | -64.81M▲ 0% | -51.98M▲ 19.8% | -60.46M▼ 16.3% | -81.04M▼ 34.0% | 124.16M▲ 253.2% | -54.17M▼ 143.6% | -52.34M▲ 3.4% | -26.43M▲ 49.5% | -17.41M▲ 34.1% | -24.17M▲ 0% |
Pretax Margin % | - | - | - | -642.26% | 59.58% | -3604.66% | -13351.79% | -4670.14% | -240.13% | -339.33% |
Income Tax | -80.31K | 0 | 0 | 0 | 1.33M | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0.12% | 0% | 0% | 0% | 1.07% | 0% | 0% | 0% | 0% | 0% |
Net Income | -64.81M▲ 0% | -51.98M▲ 19.8% | -60.46M▼ 16.3% | -81.04M▼ 34.0% | 122.83M▲ 251.6% | -54.17M▼ 144.1% | -52.34M▲ 3.4% | -26.43M▲ 49.5% | -17.41M▲ 34.1% | -24.17M▲ 0% |
Net Margin % | - | - | - | -642.26% | 58.95% | -3604.66% | -13351.79% | -4670.14% | -240.13% | -339.33% |
Net Income Growth % | -189.13% | 19.79% | -16.32% | -34.03% | 251.58% | -144.1% | 3.38% | 49.5% | 34.12% | 3.23% |
Net Income (Continuing) | -64.81M | -51.98M | -60.46M | -81.04M | 122.83M | -54.17M | -52.34M | -26.43M | -17.41M | -24.17M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -3.35▲ 0% | -2.11▲ 37.0% | -1.51▲ 28.4% | -1.39▲ 7.9% | 1.76▲ 226.6% | -0.77▼ 143.8% | -0.74▲ 3.9% | -0.37▲ 50.0% | -0.24▲ 35.1% | -0.33▲ 0% |
EPS Growth % | -193.86% | 37.01% | 28.44% | 7.95% | 226.62% | -143.75% | 3.9% | 50% | 35.14% | 1.17% |
EPS (Basic) | -3.35 | -2.11 | -1.51 | -1.39 | 1.78 | -0.77 | -0.74 | -0.37 | -0.24 | - |
Diluted Shares Outstanding | 19.34M | 24.63M | 39.22M | 58.45M | 68.07M | 70.42M | 70.58M | 70.91M | 73.74M | 73.74M |
Basic Shares Outstanding | 19.34M | 24.63M | 39.22M | 58.45M | 67.48M | 70.42M | 70.58M | 70.91M | 73.74M | 73.74M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
OVID Balance Sheet
Ovid Therapeutics Inc. (OVID) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 88.59M | 44.27M | 79.81M | 74.84M | 190.48M | 131.38M | 109.6M | 55.94M | 90.45M | 160.15M |
Cash & Short-Term Investments | 87.13M | 41.5M | 76.74M | 72.03M | 187.8M | 129M | 105.83M | 53.08M | 69.64M | 155.52M |
Cash Only | 87.13M | 36.49M | 41.9M | 72.03M | 187.8M | 44.87M | 27.04M | 26.3M | 13.15M | 94.06M |
Short-Term Investments | 0 | 5.01M | 34.84M | 0 | 0 | 84.13M | 78.79M | 26.77M | 56.48M | 61.46M |
Accounts Receivable | 0 | 0 | 1.13M | 141.76K | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | 4.1 | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 600.1K | 0 | 0 | 2.68M | 1 | 1K | 0 | 20.81M | 4.62M |
Total Non-Current Assets | 869.55K | 3.38M | 1.03M | 1.08M | 4.07M | 23.89M | 34.43M | 36.23M | 60.49M | 65.48M |
Property, Plant & Equipment | 51.77K | 69.87K | 68.36K | 135.62K | 242.76K | 16.07M | 14.66M | 13.23M | 0 | 11.52M |
Fixed Asset Turnover | - | - | - | 93.03x | 858.40x | 0.09x | 0.03x | 0.04x | - | 0.79x |
Goodwill | 0 | 0 | -247 | 100 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 124.19K | 391.87K | 467.25K | 318.9K | 164K | 222.1K | 200K | 92K | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 3.56M | 5.62M | 17.63M | 20.97M | 64.7M | 148.48M |
Other Non-Current Assets | 693.59K | 2.92M | 495.18K | 627.8K | 96.13K | 1.97M | 1.94M | 1.93M | -4.22M | 12.01M |
Total Assets | 89.46M▲ 0% | 47.65M▼ 46.7% | 80.84M▲ 69.7% | 75.93M▼ 6.1% | 194.54M▲ 156.2% | 155.27M▼ 20.2% | 144.03M▼ 7.2% | 92.17M▼ 36.0% | 150.93M▲ 63.8% | 225.63M▲ 0% |
Asset Turnover | - | - | - | 0.17x | 1.07x | 0.01x | 0.00x | 0.01x | 0.05x | 0.06x |
Asset Growth % | 68.7% | -46.73% | 69.66% | -6.08% | 156.23% | -20.19% | -7.24% | -36.01% | 63.76% | 167.85% |
Total Current Liabilities | 6.02M | 8.84M | 10.53M | 22.06M | 14.8M | 6.99M | 11.47M | 10.52M | 8.29M | 15.75M |
Accounts Payable | 2.03M | 3.76M | 3.26M | 5.45M | 7.13M | 1.95M | 3.7M | 3.19M | 1.96M | 8.88M |
Days Payables Outstanding | 9.21K | 9.67K | - | - | - | - | - | - | 2.38K | 43K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.46M |
Deferred Revenue (Current) | 0 | 0 | 0 | 2.21M | 0 | 0 | 0 | 0 | 0 | 718K |
Other Current Liabilities | 2.08M | 2.31M | 4.55M | 8.19M | 3.91M | 0 | 0 | 1K | 0 | 5.41M |
Current Ratio | 14.71x | 5.01x | 7.58x | 3.39x | 12.87x | 18.79x | 9.55x | 5.32x | 10.91x | 10.17x |
Quick Ratio | 14.71x | 5.01x | 7.58x | 3.39x | 12.87x | 18.79x | 9.55x | 5.32x | 10.91x | 10.17x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 0 | 286.56K | 10.23M | 0 | 16M | 44.76M | 13.42M | 11.99M | 11.61M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 16M | 14.76M | 13.42M | 11.99M | 37.05M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 286.56K | 61.2K | 0 | 1 | 30M | 0 | 0 | 11.61M |
Total Liabilities | 6.02M | 8.84M | 10.82M | 32.29M | 14.8M | 22.99M | 56.23M | 23.94M | 20.27M | 27.36M |
Total Debt | 0 | 0 | 0 | 0 | 0 | 16.54M | 16M | 14.76M | 13.42M | 1.46M |
Net Debt | -87.13M | -36.49M | -41.9M | -72.03M | -187.8M | -28.33M | -11.04M | -11.55M | 266K | -92.61M |
Debt / Equity | - | - | - | - | - | 0.13x | 0.18x | 0.22x | 0.10x | 0.01x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.03x |
Net Debt / EBITDA | - | - | - | - | -1.51x | - | - | - | - | 1.95x |
Interest Coverage | - | - | - | - | - | - | - | - | - | - |
Total Equity | 83.44M▲ 0% | 38.81M▼ 53.5% | 70.02M▲ 80.4% | 43.63M▼ 37.7% | 179.75M▲ 312.0% | 132.27M▼ 26.4% | 87.8M▼ 33.6% | 68.23M▼ 22.3% | 130.66M▲ 91.5% | 198.27M▲ 0% |
Equity Growth % | 69.26% | -53.49% | 80.45% | -37.69% | 311.96% | -26.41% | -33.62% | -22.29% | 91.51% | 247.34% |
Book Value per Share | 4.31 | 1.58 | 1.79 | 0.75 | 2.64 | 1.88 | 1.24 | 0.96 | 1.77 | 2.69 |
Total Shareholders' Equity | 83.44M | 38.81M | 70.02M | 43.63M | 179.75M | 132.27M | 87.8M | 68.23M | 130.66M | 198.27M |
Common Stock | 24.61K | 24.65K | 54.71K | 65.74K | 70.36K | 70.47K | 71K | 71K | 130K | 167K |
Retained Earnings | -100.72M | -152.7M | -213.16M | -294.19M | -171.36M | -225.53M | -277.87M | -304.3M | -321.71M | -338.7M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -50.91K | -1.83K | 2.47K | 0 | 0 | -42.19K | 0 | -35K | -202K | -422K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OVID Cash Flow Statement
Ovid Therapeutics Inc. (OVID) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -31.47M | -45.56M | -51.09M | -51.58M | 118.61M | -55.23M | -45.78M | -55.96M | -38.33M | -41.95M |
Operating CF Margin % | - | - | - | -408.84% | 56.92% | -3675.08% | -11678.81% | -9886.22% | -528.6% | - |
Operating CF Growth % | -76.78% | -44.77% | -12.14% | -0.97% | 329.94% | -146.56% | 17.1% | -22.23% | 31.49% | 41.54% |
Net Income | -64.81M | -51.98M | -60.46M | -81.04M | 119.84M | -54.17M | -52.34M | -26.43M | -17.41M | -24.17M |
Depreciation & Amortization | 80.31K | 141.73K | 255K | 306.85K | 237K | 1.38M | 1.6M | 613K | 273K | 168K |
Stock-Based Compensation | 6.4M | 7.06M | 5.21M | 7.53M | 0 | 6.56M | 7.29M | 6.28M | 4.81M | 2.41M |
Deferred Taxes | 0 | 4.61K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 25.86M | -1.24K | -29.63K | -199.41K | 15.35M | -764.94K | -4.71M | -36.26M | -21.9M | -19.9M |
Working Capital Changes | 996.85K | -787.91K | 3.94M | 21.82M | -16.81M | -8.23M | 2.39M | -150K | -4.1M | -469K |
Change in Receivables | 7.37K | 0 | -531.04K | 989.38K | 141.76K | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 1.08M | 1.65M | -653.95K | 2.33M | 1.7M | -5.17M | 1.75M | -512K | -1.23M | 3.63M |
Cash from Investing | -47.39K | -5.36M | -30.04M | 34.65M | -1.82M | -87.88M | -2.58M | 54.59M | -49.85M | -49.01M |
Capital Expenditures | -47.39K | -352.02K | -57.16K | -127.24K | -189.41K | -1.42M | -40.31K | -71K | 0 | 0 |
CapEx % of Revenue | - | - | - | 1.01% | 0.09% | 94.41% | 10.28% | 12.54% | - | 0% |
Acquisitions | 0 | 318.15K | 0 | 0 | 0 | -2.5M | -10M | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -8.48K | -318.15K | -186.89K | -263.44K | 0 | -1M | -97.15K | -89K | 0 | 0 |
Cash from Financing | 66.7M | 286.14K | 86.54M | 47.07M | 904.08K | 180.66K | 30.54M | 622K | 75.21M | 164.18M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 30M | 0 | 0 | 0 |
Equity Issued (Net) | 69.75M | 0 | 86.41M | 46.73M | 925.4K | 180.66K | 535.2K | 622K | 75.21M | 164.18M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -3.05M | 286.14K | 131.9K | 341.04K | -21.31K | 0 | 0 | 0 | 0 | 0 |
Net Change in Cash | 35.19M▲ 0% | -50.64M▼ 243.9% | 5.41M▲ 110.7% | 30.14M▲ 457.3% | 115.76M▲ 284.1% | -142.93M▼ 223.5% | -17.83M▲ 87.5% | -740K▲ 95.8% | -13.15M▼ 1676.8% | 72.93M▲ 0% |
Free Cash Flow | -31.52M▲ 0% | -45.91M▼ 45.7% | -51.33M▼ 11.8% | -51.97M▼ 1.2% | 118.43M▲ 327.9% | -56.65M▼ 147.8% | -45.92M▲ 18.9% | -56.03M▼ 22.0% | -38.33M▲ 31.6% | -41.95M▲ 0% |
FCF Margin % | - | - | - | -411.93% | 56.83% | -3769.49% | -11713.87% | -9898.76% | -528.6% | -589.06% |
FCF Growth % | -75.18% | -45.67% | -11.81% | -1.25% | 327.86% | -147.83% | 18.94% | -22.01% | 31.58% | 15.42% |
FCF per Share | -1.63 | -1.86 | -1.31 | -0.89 | 1.74 | -0.80 | -0.65 | -0.79 | -0.52 | -0.57 |
FCF Conversion (FCF/Net Income) | 0.49x | 0.88x | 0.85x | 0.64x | 0.97x | 1.02x | 0.87x | 2.12x | 2.20x | 1.74x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OVID Key Ratios
Ovid Therapeutics Inc. (OVID) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -97.65% | -85.04% | -111.11% | -142.6% | 109.98% | -34.72% | -47.57% | -33.88% | -17.51% | -22.51% |
Return on Invested Capital (ROIC) | - | - | -302.59% | - | - | -86.89% | -49.21% | -69.57% | -33.93% | -45.33% |
Gross Margin | - | - | - | 100% | 100% | 100% | 100% | 100% | 95.86% | 99.51% |
Net Margin | - | - | - | -642.26% | 58.95% | -3604.66% | -13351.79% | -4670.14% | -240.13% | -339.33% |
Debt / Equity | - | - | - | - | - | 0.13x | 0.18x | 0.22x | 0.10x | 0.01x |
FCF Conversion | 0.49x | 0.88x | 0.85x | 0.64x | 0.97x | 1.02x | 0.87x | 2.12x | 2.20x | 1.74x |
Revenue Growth | - | - | - | - | 1551.57% | -99.28% | -73.91% | 44.39% | 1181.27% | 1199.63% |
Related:OVID Dividend History·OVID Revenue History·OVID Price History·OVID P/E History·OVID Financial Ratios·OVID Institutional Holders
OVID SEC Filings & Documents
Ovid Therapeutics Inc. (OVID) SEC filings — annual & quarterly reports (10-K, 10-Q)
OVID Frequently Asked Questions
Ovid Therapeutics Inc. (OVID) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Ovid Therapeutics Inc. (OVID) reported $7.1M in revenue for fiscal year 2025.
Ovid Therapeutics Inc. (OVID) grew revenue by 1181.3% over the past year. This is strong growth.
Ovid Therapeutics Inc. (OVID) reported a net loss of $24.2M for fiscal year 2025.
Dividend & Returns
Ovid Therapeutics Inc. (OVID) has a return on equity (ROE) of -17.5%. Negative ROE indicates the company is unprofitable.
Ovid Therapeutics Inc. (OVID) had negative free cash flow of $42.0M in fiscal year 2025, likely due to heavy capital investments.